Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boston ScientificBSX -0.91%77 3-Year EBITDA Growth Rate is 21.40% as of Jun. 2026, which is 21% above its 10-year median of 17.75. GuruFocus rates BSX with a GF Score™ of 77/100 and a GF Value™ of $107.11 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Boston Scientific ranks better than 67.44% on this metric.
During the past 12 months, Boston Scientific's average EBITDA Per Share Growth Rate was 21.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Boston Scientific was 83.10% per year. The lowest was -271.10% per year. And the median was 17.75% per year.
Boston Scientific (NYSE:BSX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Boston Scientific 3-Year EBITDA Growth Rate Related Terms
BSX vs EW, DXCM, GEHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Boston Scientific's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Boston Scientific's 3-Year EBITDA Growth Rate falls into.
Boston Scientific 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.40% mean?
Boston Scientific (BSX) has a 3-Year EBITDA Growth Rate of 21.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Boston Scientific and its competitors. This is 21% above median its historical median of 17.75. According to the industry distribution chart, Boston Scientific ranks #224 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 32.6%.
Is Boston Scientific's 3-Year EBITDA Growth Rate too high?
Boston Scientific's current 3-Year EBITDA Growth Rate of 21.40% is 21% above median its 10-year median of 17.75. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Boston Scientific's value of 21.40% is 170.9% above this industry median. Based on the distribution chart, Boston Scientific ranks #224 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boston Scientific has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's 3-Year EBITDA Growth Rate compare to EW and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #224 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Boston Scientific in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Boston Scientific's value of 21.40% is 170.9% above this benchmark. While the company's 10-year median is 17.75 vs. the industry median of 7.90, Boston Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current 3-Year EBITDA Growth Rate of 21.40% is 170.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Boston Scientific and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current 3-Year EBITDA Growth Rate is 21.40%, which is 21% above median its own 10-year median of 17.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $107.11, compared to a current price of $47.86 — trading 55.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.40%, which is 21% above median its 10-year median of 17.75 and 170.9% above the Medical Devices & Instruments industry median of 7.90. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Boston Scientific (BSX), the current 3-Year EBITDA Growth Rate is 21.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of $47.86 is trading 55.3% below its estimated GF Value™ of $107.11.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for BSX:
3-Year EBITDA Growth Rate: 21.40% (21% above median its 10-year median of 17.75)
GF Value™: $107.11 vs. price of $47.86 (55.3% below fair value)
Industry Position: 170.9% above the Medical Devices & Instruments median (#224 of 688)
No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score
Get the complete analysis for BSX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSX has been successfully added to your 
